Antivitamines K et pharmacogénétique: vers une meilleure compréhension de la variabilité individuelle de l'effet dose–réponse

Stafford, 2005, The vitamin K cycle, J. Thromb. Haemost., 3, 1873, 10.1111/j.1538-7836.2005.01419.x Rost, 2004, Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2, Nature, 427, 537, 10.1038/nature02214 Li, 2004, Identification of the gene for vitamin K epoxide reductase, Nature, 427, 541, 10.1038/nature02254 Ansell, 2004, The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy, Chest, 126, 204S, 10.1378/chest.126.3_suppl.204S Kirchheiner, 2005, Clinical consequences of cytochrome P450 2C9 polymorphisms, Clin. Pharmacol. Ther., 77, 1, 10.1016/j.clpt.2004.08.009 Penning-van Beest, 2001, Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation, Thromb. Haemost, 86, 569, 10.1055/s-0037-1616088 Visser, 2002, Overanticoagulation associated with combined use of antibacterial drugs and acenocoumarol or phenprocoumon anticoagulants, Thromb. Haemost., 88, 705, 10.1055/s-0037-1613289 Franco, 2004, Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols, Am. J. Med., 116, 651, 10.1016/j.amjmed.2003.12.036 Aithal, 1999, Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, Lancet, 353, 717, 10.1016/S0140-6736(98)04474-2 Margaglione, 2000, Genetic modulation of oral anticoagulation with warfarin, Thromb. Haemost., 84, 775, 10.1055/s-0037-1614114 Taube, 2000, Influence of cytochrome P450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment, Blood, 96, 1816, 10.1182/blood.V96.5.1816 Higashi, 2002, Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy, JAMA, 287, 1690, 10.1001/jama.287.13.1690 Kamali, 2004, Contribution of age and body size and CYP2C9 genotype to anticoagulant, Clin. Pharmacol. Ther., 75, 204, 10.1016/j.clpt.2003.10.001 Siguret, 2004, Polymorphismes du cytochrome P450 2C9 (CYP2C9) et posologie à l’équilibre pour des patients âgés traités par warfarine, Rev. Med. Intern., 25, 271, 10.1016/j.revmed.2003.11.006 Gage, 2004, Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin, Thromb. Haemost., 91, 87, 10.1160/TH03-06-0379 Bodin, 2005, Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity, Blood, 106, 135, 10.1182/blood-2005-01-0341 Visser, 2004, The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon, Pharmacogenetics, 14, 27, 10.1097/00008571-200401000-00003 Visser, 2004, The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon, Thromb. Haemost., 92, 61, 10.1160/TH03-12-0741 Verstuyft, 2003, Genetic and environmental risk factors for oral anticoagulant overdose, Eur. J. Clin. Pharmacol., 58, 739, 10.1007/s00228-002-0538-2 D'Andrea, 2005, A polymorphism in VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin, Blood, 105, 645, 10.1182/blood-2004-06-2111 Rieder, 2005, Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose, N. Engl. J. Med., 352, 2285, 10.1056/NEJMoa044503 Veenstra, 2005, Association of vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in Hong Kong Chinese patient population, Pharmacogenet. Genomics, 15, 687, 10.1097/01.fpc.0000174789.77614.68 Reitsma, 2005, C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk, PLoS Med., 2, 310, 10.1371/journal.pmed.0020312 Schalekamp, 2006, VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation, Clin. Pharmacol. Ther., 80, 13, 10.1016/j.clpt.2006.04.006 Sconce, 2005, The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen, Blood, 106, 2329, 10.1182/blood-2005-03-1108 Aquilante, 2006, Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements, Clin. Pharmacol. Ther., 79, 291, 10.1016/j.clpt.2005.11.011 Gage, 2006, Pharmacogenetics-based coumarin therapy, Hematology (Am. Soc. Hematol. Educ. Program), 467, 10.1182/asheducation-2006.1.467